gp100:209-217 (210M)

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

High-Risk MelanomaMelanomaNeoplasm Metastasis

Phase 2

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

CompletedNCT00001832

National Cancer Institute (NCI)Melanoma, Neoplasm Metastasis

Start: 1999-08-31End: 2010-05-31Updated: 2012-12-21

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

CompletedNCT00273910

National Cancer Institute (NCI)High-Risk Melanoma

Start: 2006-01-31End: 2010-05-31Updated: 2012-10-19

Related Papers

Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.

2012-05-03170 citations